[Interferon-alpha in cutaneous T-cell lymphoma].
There exists a variety of treatment modalities for cutaneous T-cell lymphoma (CTCL) which are used according to localization and extension of the disease. Additionally, in the last years it has been demonstrated by several groups that interferon-alpha (IFN-alpha) therapy dependent on stage of the disease results in response rates of 40 to 50%. We could demonstrate that the combination of low dose IFN with retinoids is able to induce long term remissions with low incidence of side effects. Other combinations of IFN-alpha with standard therapies and/or experimental therapies (Pentostatin) seem to contribute-according to preliminary data-to an improvement of remission rates in CTCL.
Knobler
R
R
Abteilung für Spezielle Dermatologie und Umweltdermatosen, Dermatologischen Universitätsklinik Wien.
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D016410:Lymphoma, T-Cell, Cutaneous / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Interferon-alpha beim kutanen T-Zell-Lymphom.